Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/08—Antiepileptics; Anticonvulsants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/22—Anxiolytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

• the present invention relates a method for inhibiting adenosine kinase by administering 5,6,7-trisubstituted-4-aminopyrido[2,3-d]pyrimidine compounds, to pharmaceutical compositions containing such compounds, as well as novel 5,6,7-trisubstituted- 4-aminopyrido[2,3-d]pyrimidine compounds.
• Adenosine kinase (ATP:adenosine 5'-phosphotransferase, EC 2.7.1.20) is a ubiquitous enzyme which catalyzes the phosphorylation of adenosine to AMP, using ATP, preferentially, as the phosphate source.
• Adenosine kinase has broad tissue and species distribution, and has been isolated from yeast, a variety of mammalian sources and certain microorganisms. It has been found to be present in virtually every human tissue assayed including kidney, liver, brain, spleen, placenta and pancreas.
• Adenosine kinase is a key enzyme in the control of the cellular concentrations of adenosine.
• Adenosine is a purine nucleoside that is an intermediate in the pathways of purine nucleotide degradation and salvage. Adenosine also has many important physiologic effects, many of which are mediated through the activation of specific ectocellular receptors, termed
• Pi receptors (Burnstock, in Cell Membrane Receptors for Drugs and Hormones, 1978, (Bolis and Straub, eds.) Raven, New York, pp. 107-118; Fredholm, et al, Pharmacol. Rev. 1994, 46: 143-156).
• adenosine inhibits the release of certain neurotransmitters (Corradetti, et al, Eur. J. Pharmacol. 1984, 104: 19-26), stabilizes membrane potential (Rudolphi, et al, Cerebrovasc. Brain Metab. Rev. 1992, 4: 346-360), functions as an endogenous anticonvulsant (Dragunow, Trends Pharmacol. Sci. 1986, 7: 128- 130) and may have a role as an endogenous neuroprotective agent (Rudolphi, et a , Trends Pharmacol. Sci., 1992, 13: 439-445).
• Adenosine may play a role in several disorders of the central nervous system such as schizophrenia, anxiety, depression and Parkinson's disease.
• schizophrenia anxiety, depression and Parkinson's disease.
• Parkinson's disease adenosine may play a role in several disorders of the central nervous system such as schizophrenia, anxiety, depression and Parkinson's disease.
• Adenosine has also been implicated in modulating transmission in pain pathways in the spinal cord (Sawynok, et al, Br. J. Pharmacol, 1986, 88: 923-930), and in mediating the analgesic effects of morphine (Sweeney, et al, J. Pharmacol. Exp. Ther. 1987, 243: 657-665).
• adenosine inhibits certain neutrophil functions and exhibits anti-inflammatory effects (Cronstein, /. Appl. Physiol. 1994, 76: 5-13).
• An AK inhibitor has been reported to decrease paw swelling in a model of adjuvant arthritis in rats (Firestein, et.al.
• Adenosine also exerts a variety of effects on the cardiovascular system, including vasodilation, impairment of atrioventricular conduction and endogenous cardioprotection in myocardial ischemia and reperfusion (Mullane and Williams, in Adenosine and Adenosine Receptors, 1990 (Williams, ed.) Humana Press, New Jersey, pp. 289-334).
• the widespread actions of adenosine also include effects on the renal, respiratory, gastrointestinal and reproductive systems, as well as on blood cells and adipocytes.
• Adenosine via its Al receptor activation on adipocytes, plays a role in diabetes by inhibiting lipolysis [Londos, et al, Proc. Natl. Acad. Sci. USA, 1980, 77, 2551.
• Endogenous adenosine release appears to have a role as a natural defense mechanism in various pathophysiologic conditions, including cerebral and myocardial ischemia, seizures, pain, inflammation and sepsis. While adenosine is normally present at low levels in the extracellular space, its release is locally enhanced at the site(s) of excessive cellular activity, trauma or metabolic stress. Once in the extracellular space, adenosine activates specific extracellular receptors to elicit a variety of responses which tend to restore cellular function towards normal (Bruns, Nucleosides Nucleotides, 1991, 10: 931-943; Miller and Hsu, J. Neurotrauma, 1992, 9: S563-S577). Adenosine has a half-life measured in seconds in extracellular fluids (Moser, et al.. Am. J. Physiol. 1989, 25: C799-C806), and its endogenous actions are therefore highly localized.
• adenosine kinase can result in augmentation of the local adenosine concentrations at foci of tissue injury, further enhancing cytoprotection. This effect is likely to be most pronounced at tissue sites where trauma results in increased adenosine production, thereby minimizing systemic toxicities.
• Pharmacologic compounds directed towards adenosine kinase inhibition provide potentially effective new therapies for disorders benefited by the site- and event-specific potentiation of adenosine.
• Disorders where such compounds may be useful include ischemic conditions such as cerebral ischemia, myocardial ischemia, angina, coronary artery bypass graft surgery (CABG), percutaneous transluminal angioplasty (PTCA), stroke, other thrombotic and embolic conditions, and neurological disorders such as epilepsy, anxiety, schizophrenia, nociperception including pain perception, neuropathic pain, visceral pain, as well as inflammation, arthritis, immunosuppression, sepsis, diabetes and gastrointestinal disfunctions such as abnormal gastrointestinal motility.
• ischemic conditions such as cerebral ischemia, myocardial ischemia, angina, coronary artery bypass graft surgery (CABG), percutaneous transluminal angioplasty (PTCA), stroke, other thrombotic and embolic conditions
• neurological disorders such as epilepsy
• a number of compounds have been reported to inhibit adenosine kinase. The most potent of these include 5'-amino-5'-deoxyadenosine (Miller, et al, J. Biol Chem. 1979, 254: 2339-2345), 5-iodotubercidin (Wotring and Townsend, Cancer Res. 1979, 39: 3018-3023) and 5'-deoxy-5-iodotubercidin (Davies, et al, Biochem. Pharmacol. 1984, 33: 347-355). Adenosine kinase is also responsible for the activation of many pharmacologically active nucleosides (Miller, et al, J. Biol Chem.
• purine nucleoside analogs represent an important group of antimetabolites which possess cytotoxic, anticancer and antiviral properties. They serve as substrates for adenosine kinase and are phosphorylated by the enzyme to generate the active form. The loss of adenosine kinase activity has been implicated as a mechanism of cellular resistance to the pharmacological effects of these nucleoside analogs (e.g. Bennett, et al, Mol. Pharmacol, 1966, 2: 432-443; Caldwell, et al, Can. J.
• dATP deoxyadenosine triphosphate
• Chem., 31B: 719-720 (1992) disclose 4-amino-5-(4-chlorophenyl)-7-(4-nitrophenyl)pyrido[2,3-d]pyrimidine and 4-amino-5-(4-methoxyphenyl)-7-(4-nitrophenyl)pyrido[2,3-d]pyrimidine compounds having antibacterial activity.
• Prakash et al, Pharmazie, 48: 221-222 (1993)) disclose 4-amino-5-phenyl-7-(4- aminophenyl)pyrido[2,3-d]pyrimidine, 4-amino-5-phenyl-7-(4-bromophenyl)pyrido[2,3- d]pyrimidine, 4-amino-5-(4-methoxyphenyl)-7-(4-aminophenyl)pyrido[2,3-d]pyrimidine, and 4-amino-5-(4-methoxyphenyl)-7-(4-bromophenyl)pyrido[2,3-d]pyrimidine compounds having antifungal activity.
• Tetrahedron, 5_1: 10253-10258 (1995)) discloses the synthesis of 4-amino-5,7-diphenylpyrido[2,3-d]pyrimidine compounds from acyclic precursors.
• Bridges et ⁇ /.(PCT application WO 95/19774, published July 27, 1995) disclose various bicyclic heteroaromatic compounds as having utility for inhibiting tyrosine kinase of epidermal growth factors. Summary Of The Invention
• the present invention provides for 5,6,7-trisubstituted-4-aminopyrido[2,3- djpyrimidine compounds having utility as adenosine kinase inhibitors.
• the present invention provides compounds having the formula (I)
• R 1 and R 2 are independently H, loweralkyl, arylalkyl or acyl, or may be taken together with the nitrogen atom to which they are attached to form a 5-to-7 membered ring optionally containing 1-3 additional heteroatoms selected from N, O or S;
• R 3 , R4 and R ⁇ are independently selected from loweralkyl, loweralkenyl, loweralkynyl, lower cycloalkyl, aryl, arylalkyl, heteroaryl, or a heterocyclic group and the dashed lines indicate a double bond is optionally present.
• the present invention also relates to a compound of formula II
• R 1 and R 2 are independently H, loweralkyl, arylalkyl or acyl, or may be taken together with the nitrogen atom to which they are attached to form a 5-to-7 membered ring optionally containing 1-3 additional heteroatoms selected from N, O or S; and R 3 , R 4 and R 5 are independently selected from loweralkyl, loweralkenyl, loweralkynyl, lower cycloalkyl, aryl, arylalkyl, heteroaryl, or a heterocyclic group.
• the present invention provides a method for inhibiting adenosine kinase by administering a compound of formula (I) or (II).
• the method of inhibiting adenosine kinase comprises exposing an adenosine kinase to an effective inhibiting amount of a compound of Formula I or II of the present invention.
• the adenosine kinase is located in vivo, the compound is administered to the organism.
• the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I or II above in combination with a pharmaceutically acceptable carrier.
• the present invention provides a method of treating ischemia, neurological disorders, nociperception , inflammation, immunosuppression, gastrointestinal disfunctions, diabetes and sepsis in a mammal in need of such treatment, comprising administering to the mammal a therapeutically effective amount of a compound of Formula I or II of the present invention.
• the present invention provides a method of treating cerebral ischemia, myocardial ischemia, angina, coronary artery bypass graft surgery, percutaneous transluminal angioplasty, stroke, thrombotic and embolic conditions, epilepsy, anxiety, schizophrenia, pain perception, neuropathic pain, visceral pain, arthritis, sepsis, diabetes and abnormal gastrointestinal motility in a mammal in need of such treatment, comprising administering to the mammal a therapeutically effective amount of a compound of Formula I or II of the present invention.
• the present invention also contemplates the use of pharmaceutically acceptable salts and amides of the compounds of Formula I or II.
• the present invention provides a process for the preparation of a compound having the formula
• R 1 and R 2 are independently H, loweralkyl, arylalkyl or acyl, or may be taken together with the nitrogen atom to which they are attached to form a 5-to-7 membered ring optionally containing 1-3 additional heteroatoms selected from N, O or S; and R 3 and R ⁇ are independently selected from loweralkyl, loweralkenyl, loweralkynyl, lower cycloalkyl, aryl, arylalkyl, heteroaryl, or a heterocyclic group; and
• R5 is selected from an aryl, heteroaryl or heterocyclic group; the method comprising
• the present invention provides a process for the preparation of compounds having the formula
• R 1 and R 2 are independently H, loweralkyl, arylalkyl or acyl, or may be taken together with the nitrogen atom to which they are attached to form a 5-to-7 membered ring optionally containing 1-3 additional heteroatoms selected from N, O or S; and
• R 3 and R are independently selected from loweralkyl, loweralkenyl, loweralkynyl, lower cycloalkyl, aryl, arylalkyl, heteroaryl, or a heterocyclic group; and R5 is selected from an aryl, heteroaryl or heterocyclic group; with the proviso that not both R 1 and R 2 are H, the method comprising
• the present invention provides a process for the preparation of compounds having the formula
• R 1 and R 2 are independently H, loweralkyl, arylalkyl or acyl, or may be taken together with the nitrogen atom to which they are attached to form a 5-to-7 membered ring optionally containing 1-3 additional heteroatoms selected from N, O or S; and R 3 and R ⁇ are independently selected from loweralkyl, loweralkenyl, loweralkynyl, lower cycloalkyl, aryl, arylalkyl, heteroaryl, or a heterocyclic group; and
• R5 is selected from an aryl, heteroaryl or heterocyclic group; the method comprising (a) reacting an aryl, heteroaryl, or a heterocyclic bromide having the formula R 5 -Br with a carboxylic acid derivative having the formula R 4 -CH -CO-Y, wherein Y is OH or Cl, and R 4 is loweralkyl, loweralkenyl, loweralkynyl, aryl, arylalkyl, heteroaryl, or a heterocyclic group, with N,0-dimetnylhydroxylamine hydrochloride, l-(3-dimethylaminopropyl)-3-ethylcarbodiimide or 1-hydroxybenzotriazole hydrate and triethylamine, and isolating a first intermediate compound having the formula R 5 -CO-CH 2 -R 4 ;
• the present invention provides a process for the preparation of compounds having the formula
• R 1 and R 2 are independently H, loweralkyl, arylalkyl or acyl, or may be taken together with the nitrogen atom to which they are attached to form a 5-to-7 membered ring optionally containing 1-3 additional heteroatoms selected from N, O or S; and
• R 3 and R ⁇ are independently selected from loweralkyl, loweralkenyl, loweralkynyl, aryl, arylalkyl, heteroaryl, or a heterocyclic group;
• R 5 is selected from an aryl, heteroaryl or heterocyclic group, with the proviso that not both R 1 and R 2 are hydrogen, the method comprising
• the present invention relates to novel 5,6,7-trisubstituted-4-aminopyrido[2,3- djpyrimidine compounds of Formula (I) above that are useful in inhibiting adenosine kinase, a method of inhibiting adenosine kinase with such compounds, to pharmaceutical compositions containing such compounds, to a method of using such compounds for inhibiting adenosine kinase, and to novel 5,6,7-trisubstituted-4-aminopyrido[2,3-d]pyrimidine compounds.
• the present invention relates to a compound of formula I or II as described above wherein:
• R 1 and R 2 are independently selected from H, loweralkyl, arylC ⁇ -C6alkyl, -C(0)C ⁇ - C ⁇ alkyl, -C(0)aryl, -C(0)heterocyclic or may join together with the nitrogen to which they are attached to from a 5-7 membered ring optionally containing 1-2 additional heteroatoms selected from O, N or S;
• R3, R4 and R ⁇ are independently selected from the group consisting of:
• a compound of Formula (I) or (II) above wherein R 5 is an aryl, arylalkyl, heteroaryl or heterocyclic group or those more particular groups shown above which are within each class.
• R 5 is an aryl, arylalkyl, heteroaryl or heterocyclic group or those more particular groups shown above which are within each class.
• a compound of Formula (I) or (II) above wherein R 5 is an aryl, arylalkyl, heteroaryl or heterocyclic group or those more particular groups shown above which are within each class.
• R 5 is selected from the group consisting of: 4- (dimethylamino)phenyl; 5-dimethylamino-2-pyridinyl; 5-methoxy-2-pyridinyl; 4- methoxyphenyl; 5-methylthiophen-2-yl; 4-(N-methyl-N-(2-methoxyethyl)amino)phenyl; and thiophen-2-yl.
• R 5 is selected from the group consisting of: 4- (dimethylamino)phenyl; 5-dimethylamino-2-pyridinyl; 5-methoxy-2-pyridinyl; 4- methoxyphenyl; 5-methylthiophen-2-yl; 4-(N-methyl-N-(2-methoxyethyl)amino)phenyl; and thiophen-2-yl.
• R 5 is selected from the group consisting of: 4- (dimethylamino)phenyl; 5-dimethylamino-2-pyridinyl; 5-
• R 4 is an aryl, arylalkyl, heteroaryl or heterocyclic group or those more particular groups shown above which are within each class.
• R 4 is selected from the group consisting of: ethoxycarbonylmethyl; ethyl; 3-fluorophenyl; 3-fluoro-4-methylphenyl; 3,4-dimethoxyphenyl; 3-methoxyphenyl; 4- methoxyphenyl; pentyl; phenyl; 3-(2-propyl)phenyl; and 4-(2-propyl)phenyl.
• R 3 is an aryl, arylalkyl, heteroaryl or heterocyclic group or those more particular groups shown above which are within each class.
• R 3 is an aryl, arylalkyl, heteroaryl or heterocyclic group or those more particular groups shown above which are within each class.
• R 3 is an aryl, arylalkyl, heteroaryl or heterocyclic group or those more particular groups shown above which are within each class.
• R 3 is selected from the group consisting of: 3-bromophenyl; 3-bromo-4-fluorophenyl; 4-bromothiophen-2-yl; 3-chlorophenyl; 3,4- dimethoxyphenyl; 3-fluorophenyl; 3-fluoro-4-methylphenyl; 4-(2-propyl)phenyl; and 3- trifluoromethyl-4-fluorophenyl.
• R 3 is selected from the group consisting of: 3-bromophenyl; 3-bromo-4-fluorophenyl; 4-bromothiophen-2-yl; 3-chlorophenyl; 3,4- dimethoxyphenyl; 3-fluorophenyl; 3-fluoro-4-methylphenyl; 4-(2-propyl)phenyl; and 3- trifluoromethyl-4-fluorophenyl.
• Exemplary and preferred compounds of the invention include:
• R3, R 4 and R ⁇ groups may be independently selected from phenyl; thiophen-2-yl; 1- methyl-2-oxobenzoxazolin-5-yl; 2-(dimethylamino)-5-pyrimidinyl; 2-(N-formyl-N-methyl amino)-3-pyrimidinyl; 2-(N-(2-methoxyethyl)-N-methylamino)-5-pyrimidinyl; 5- dimethylamino-2-pyridinyl; 5-(N-(2-methoxyethyl)-N-methylamino)-2-pyridinyl; 2-(N- methylamino)-5-pyrimidinyl; 2-(l-mo ⁇ holinyl)-5-pyrimidinyl; 2-(l-pyrrolidinyl)-5- pyrimidinyl; 2-dimethylamino-5-pyrimidinyl; 2-furanyl; 2-oxobenzoxazolin-5-yl; 2-pyri
• acyl refers to a moiety attached by a carbonyl linkage, as for example, loweralkyl-carbonyl or aryl-carbonyl, wherein loweralkyl and aryl are as defined herein.
• acyl include, for example, acetyl, propionyl, hexanoyl, trifluoroacetyl, benzoyl, 4-methylbenzoyl, methoxyacetyl, pentanoyl, N-Bocglycylimidazoyl, N- phthalimidylglycyl and the like or others as specified herein.
• aryl or “substituted aryl”, as used herein, refers to a carbocyclic aromatic radical, including, for example, phenyl and 1- or 2-naphthyl, which may be unsubstituted or substituted respectively by independent replacement of one, two or three of the hydrogen atoms thereon with Cl, Br, F, I, cyano, carboxamido, hydroxy, loweralkoxy, loweralkyl, loweralkenyl, loweralkynyl, amino, loweralkylamino, di(loweralkylamino), N-loweralkyl-N- loweralkoxyamino, trifluoromethyl or methoxymethyl groups.
• aryl refers to a phenyl group substituted with one ureido, methylsulfonyl, pyrimidinyl, pyridinyl, pyridazinyl, mo ⁇ holinyl, phenyl-loweralkoxy, phenyl-loweralkenyl or cycloalkyl-loweralkyl group.
• aryl radicals include, but are not limited to, 3-bromophenyl, 3- chlorophenyl, 4-chlorophenyl, 3-methoxyphenyl, 3-(2-propyl)phenyl, 3,4-dimethoxyphenyl, 3-trifluromethylphenyl, 3-trifluoro-4-fluorophenyl, 4-(N-methyl-N- methoxyl)ethylaminophenyl, 4-dimethylaminophenyl, 3-fluoro-4-methylphenyl, 4- methylphenyl, 4-cyanophenyl, 4-propylmethyl, 3,5-dichlorophenyl, 3,4- methylenedioxyphenyl, 3-cyanopropylphenyl, 4-ureidophenyl, 3-methylsulfonylphenyl, 3- carboxamidopropylphenyl or others as shown herein.
• arylalkyl refers to a loweralkyl radical having appended thereto an aryl group, as defined above, as for example benzyl and phenylethyl.
• aryloxy refers to a aryl radical which is appended to the molecule via an ether linkage (i.e., through an oxygen atom), as for example phenoxy, naphthyloxy, 4- chlorophenoxy, 4-methylphenoxy, 3,5-dimethoxyphenoxy, and the like.
• cycloalkyl refers to a cyclic saturated hydrocarbon radical having from 3 to 7 ring atoms.
• examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. Cycloalkyl is also described as C3-Cscycloalkyl.
• cycloalkyl-loweralkyl refers to a loweralkyl radical as defined below substituted with a cycloalkyl group as defined above by replacement of one hydrogen atom.
• examples of cycloalkyl-loweralkyl include cyclopropylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclohexylmethyl and cycloheptylbutyl, and the like.
• heteroaryl or “substituted heteroaryl” refers to a monocyclic aromatic radical having from five to seven ring atoms of which one ring atom is nitrogen, oxygen or sulfur, zero, one or two ring atoms are additional heteroatoms independently selected from S, O and N; and the remaining ring atoms are carbon, the radical being joined to the rest of the molecule via any of the ring atoms.
• a heteroaryl group may be unsubstituted or substituted by independent replacement of one, two or three of the hydrogen atoms thereon with Cl, Br, F, I, cyano, carboxamido, hydroxy, loweralkoxy, loweralkyl, loweralkenyl, loweralkynyl, amino, loweralkylamino, di(loweralkylamino), N-loweralkyl-N-loweralkoxyamino, trifluoromethyl or methoxymethyl groups.
• heteroaryl refers to a heteroaryl group substituted with one ureido, methylsulfonyl, pyrimidinyl, pyridinyl, pyridazinyl, mo ⁇ holinyl, phenyl-loweralkoxy, phenyl-loweralkenyl or cycloalkyl-loweralkyl group.
• a heteroaryl group may be substituted by replacement of any two adjacent hydrogen atoms with a grouping of atoms to form a fused benzene ring.
• heteroaryl examples include pyridinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, thiadiazolyl, oxadiazolyl, furanyl, thiophenyl, 5-methylthiophen-2-yl, 5-nitrothiophen-2-yl, 5- methylfuranyl, benzofuranyl, benzothiophenyl, and the like and those additionally described herein.
• heterocyclic refers to a saturated or unsaturated monocyclic ring system radical having from four to seven ring atoms of which one is nitrogen or oxygen; zero, one or two ring atoms are additional heteroatoms independently selected from S, O and N; and the remainder are carbon, the radical being joined to the rest of the molecule via any of the ring atoms and being optionally substituted, either on a nitrogen or a carbon atom, by an additional radical selected from among aryl(loweralkyl), alkoxycarbonyl, loweralkyl, halo(loweralkyl), amino(loweralkyl), hydroxy-substituted loweralkyl, hydroxy, loweralkoxy, halogen, amino, loweralkylamino, and amino, (loweralkyl)amino or alkanoylamino of from one to eight carbon atoms in which the amino group may be further substituted with alkanoyl of from one to eight carbons, an alpha-amino
• heterocyclic examples include pyrrolidine, tetrahydrofuran, dihydropyrrole, isoxazolidine, oxazolidine, tetrahydropyridine, piperidine, piperazine, mo ⁇ holine, thiomo ⁇ holine, aziridine and azetidine and those additionally described herein.
• heterocyclic-loweralkyl refers to a loweralkyl radical as defined below substituted with a heterocyclic-group as defined above by replacement of one hydrogen atom.
• examples of cycloalkyl-loweralkyl include pyrrolidinylmethyl, piperidinylethyl, and the like.
• loweralkyl refers to saturated, straight- or branched-chain hydrocarbon radicals containing from one to six carbon atoms including, which may be unsubstituted or substituted by independent replacement of one, two or three of the hydrogen atoms thereon with Cl, Br, F, I, cyano, carboxamido, hydroxy, loweralkoxy, amino, loweralkylamino, di(loweralkylamino) or N-loweralkyl-N-loweralkoxyamino groups.
• loweralkyl examples include, but are not limited to, methyl, ethyl, propyl, isopropyl, n- butyl, tert-butyl, neopentyl, n-hexyl, hydroxyethyl, methoxymethyl, trifluoromethyl, 3- cyanopropyl, 3-carboxamidopropyl, and the like.
• group "C ⁇ -C6alkyl” is described and has a similar meaning as above for loweralkyl but is more specifically recited.
• the term "Co-C6alkyl” indicates the carbon atoms which may be present in the alkyl chain including zero.
• loweralkenyl refers to mono-unsaturated straight- or branched-chain hydrocarbon radicals containing from two to six carbon atoms including, but not limited to, vinyl, propenyl, ⁇ -butenyl, /-butenyl, n-pentenyl, and n-hexenyl. These variables are also recited as, for example, C2-C6alkenyl.
• loweralkoxy refers to a loweralkyl radical which is appended to the molecule via an ether linkage (i.e., through an oxygen atom), as for example methoxy, ethoxy, propoxy, 2-propoxy, 2-methyl-2-propoxy, tert-butoxy, pentyloxy, hexyloxy, isomeric forms thereof and the like. This term is also described as C ⁇ -C6alkyloxy.
• loweralkynyl refers to straight- or branched-chain hydrocarbon radicals possessing a single triple bond and containing from two to six carbon atoms including, but not limited to, ethynyl, propynyl, i-butynyl, «-pentynyl, and n-hexynyl. This term is also described as C2-C6alkynyl.
• compositions which comprise a compound of the present invention in combination with a pharmaceutically acceptable carrier.
• the present invention includes one or more compounds, as set forth above, formulated into compositions together with one or more non-toxic physiologically tolerable or acceptable diluents, carriers, adjuvants or vehicles that are collectively referred to herein as diluents, for parenteral injection, for oral administration in solid or liquid form, for rectal or topical administration, or the like.
• diluents for parenteral injection, for oral administration in solid or liquid form, for rectal or topical administration, or the like.
• a compound of the present invention can exist in a variety of forms including pharmaceutically-acceptable salts, amides and the like.
• Compositions may be prepared that will deliver the correct amount of a compound or compounds of the invention.
• the following dosages are thought to provide the optimal therapy: iv infusions: 0.1- 250 nmol/kg/minute, preferably from 1-50 nmol kg/minute; oral: 0.01-250 ⁇ Mol/kg/day, preferably from about 0.1-50 ⁇ Mol/kg/day; these oral molar dosage ranges correspond to 0.005-125 mg/kg/day, preferably 0.05-25 mg/kg/day.
• the preferred route of administration is intravenous; the preferred method of treating chronic disorders is orally by means of a tablet or sustained release formulation.
• “Pharmaceutically-acceptable amide” refers to the pharmaceutically-acceptable, nontoxic amides of the compounds of the present invention which include amides formed with suitable organic acids or with amino acids, including short peptides consisting of from l-to-6 amino acids joined by amide linkages which may be branched or linear, wherein the amino acids are selected independently from naturally-occurring amino acids, such as for example, glycine, alanine, leucine, valine, phenylalanine, proline, methionine, tryptophan, asparagine, aspartic acid, glutamic acid, glutamine, serine, threonine, lysine, arginine, tyrosine, histidine, ornithine, and the like.
• “Pharmaceutically-acceptable salts” refers to the pharmaceutically-acceptable, nontoxic, inorganic or organic acid addition salts of the compounds of the present invention, as described in greater detail below.
• the compounds of the present invention can be used in the form of pharmaceutically- acceptable salts derived from inorganic or organic acids.
• These salts include, but are not limited to, the following: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, flavianate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexonoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2- naphthalenesulfonate, oxalate, palmate, pettinate, per
• Appropriate cationic salts are also readily prepared by conventional procedures such as treating an acid of Formula I or II with an appropriate amount of base, such as an alkali or alkaline earth metal hydroxide, e.g., sodium, potassium, lithium, calcium, or magnesium, or an organic base such as an amine, e.g., dibenzylethylenediamine, cyclohexylamine, dicyclohexylamine, triethylamine, piperidine, pyrrolidine, benzylamine, and the like, or a quaternary ammonium hydroxide such as tetramethylammonium hydroxide and the like.
• base such as an alkali or alkaline earth metal hydroxide, e.g., sodium, potassium, lithium, calcium, or magnesium
• an organic base such as an amine, e.g., dibenzylethylenediamine, cyclohexylamine, dicyclohexylamine, triethylamine, piperidine
• the basic mtrogen-containing groups can be quaternized with such agents as loweralkyl halides, such as methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dialkyl sulfates; long chain halides such as decyl, lauryl, myristyl, and stearyl chlorides, bromides and iodides; arylalkyl halides like benzyl and phenethyl bromides, and others. Water or oil-soluble or dispersible products are thereby obtained.
• loweralkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides
• dialkyl sulfates long chain halides such as decyl, lauryl, myristyl, and stearyl chlorides, bromides and iodides
• arylalkyl halides
• the salts of the present invention can be synthesized from the compounds of Formula I or II which contain a basic or acidic moiety by conventional methods, such as by reacting the free base or acid with stoichiometric amounts or with an excess of the desired salt forming inorganic acid or base in a suitable solvent or various combinations of solvents.
• pharmaceutical compositions comprising one or more of the compounds of formula (I) prepared and formulated in combination with one or more non-toxic pharmaceutically acceptable carriers compositions, in the manner described below.
• compositions suitable for parenteral injection may comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions and sterile powders for reconstitution into sterile injectable solutions or dispersions.
• suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propylene glycol, polyethylene glycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate.
• Proper fluidity may be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
• compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. Prevention of the action of microorganisms may be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example, sugars, sodium chloride and the like. Prolonged abso ⁇ tion of the injectable pharmaceutical form may be brought about by the use of agents delaying abso ⁇ tion, for example, aluminum monostearate and gelatin.
• the compounds may be inco ⁇ orated into slow-release or targeted-delivery systems, such as polymer matrices, liposomes, and microspheres. They may be sterilized, for example, by filtration through a bacteria-retaining filter, or by inco ⁇ orating sterilizing agents in the form of sterile solid compositions, which may be dissolved in sterile water, or some other sterile injectable medium immediately before use.
• Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules.
• the active compound is admixed with at least one inert customary excipient (or carrier), such as sodium citrate or dicalcium phosphate, and additionally (a) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol and silicic acid; (b) binders, as for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia; (c) humectants, as for example, glycerol; (d) disintegrating agents, as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates and sodium carbonate; (e) solution retarders, as for example paraffin; (f) abso ⁇ tion accelerators, as for example, quaternary ammonium compounds; (g) fillers
• compositions of a similar type may also be employed as fillers in soft and hard- filled gelatin capsules, using such excipients as lactose or milk sugar, as well as high molecular weight polyethylene glycols, and the like.
• Solid dosage forms such as tablets, dragees, capsules, pills and granules may be prepared with coatings and shells, such as enteric coatings and others well known in this art. They may contain pacifying agents, and may also be of such composition that they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner. Examples of embedding compositions which may be used are polymeric substances and waxes.
• the active compounds may also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned excipients.
• Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs.
• the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3- butylene glycol, dimethylformamide, oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan or mixtures of these substances, and the like.
• inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and e
• these liquid dosage forms may also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring and perfuming agents.
• Suspensions in addition to the active compounds, may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.
• compositions for rectal or vaginal administrations are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and therefore, melt in the rectum or vaginal cavity and release the active component.
• suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and therefore, melt in the rectum or vaginal cavity and release the active component.
• Dosage forms for topical or transdermal administration of a compound of this invention further include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or transdermal patches.
• Transde ⁇ nal administration via a transdermal patch is a particularly effective and preferred dosage form of the present invention.
• the active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservative, buffers or propellants as may be required. It is known that some agents may require special handling in the preparation of transdermal patch formulations. For example, compounds that are volatile in nature may require admixture with special formulating agents or with special packaging materials to assure proper dosage delivery. In addition, compounds which are very rapidly absorbed through the skin may require formulation with abso ⁇ tion-retarding agents or barriers. Ophthalmic formulations, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.
• the present compounds may also be administered in the form of liposomes.
• liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes may be used.
• the present compositions in liposome form may contain, in addition to the compounds of the present invention, stabilizers, preservatives, excipients, and the like.
• the preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic. Methods to form liposomes are known in the art. See, for example, Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N. Y., (1976), p 33 et seq.
• N-methoxy-N-methylamide compounds (3) may be prepared from the appropriate carboxylic acid derivative (1, the "R 4 reagent"), wherein Y is OH or Cl, and R 4 is loweralkyl, loweralkenyl, loweralkynyl, aryl, arylalkyl, heteroaryl, or a heterocyclic group, by treatment with N,0-dimethylhydroxylamine hydrochloride (2) and l-(3-dimethylaminopropyl)-3- ethylcarbodiimide (EDCI), t-butanol, and triethylamine.
• R 4 reagent wherein Y is OH or Cl, and R 4 is loweralkyl, loweralkenyl, loweralkynyl, aryl, arylalkyl, heteroaryl, or a heterocyclic group
• reaction may be performed in methylene chloride, or a similar suitable solvent, such as for example, toluene or THF, at ambient temperature for about 8 hours to about 24 hours.
• Compound (3) is then reacted with compounds (4, the "R 5 reagent") wherein R 5 is substituted aryl, heteroaryl, or a heterocyclic compounds to prepare compound (5) according to the literature procedure of Nahm and Weinreb (Tetrahedron Lett. 1981, 22: 3815).
• R 5 reagent wherein R 5 is substituted aryl, heteroaryl, or a heterocyclic compounds
• Compound (5) is then reacted with an appropriately substituted aldehyde (6, the "R 3 Reagent"), wherein R 3 is aryl, heteroaryl, or a heterocyclic group, and malononitrile (7) by heating in the presence of ammonium acetate, or another suitable ammonium salt, such as for example, ammonium propionate, ammonium iodide, or the like, in an suitable solvent to produce compound (8).
• suitable solvents include ethanol, benzene, toluene, methylene chloride, DMF, THF, dioxane, and the like.
• the water of the reaction may removed by use of a Dean Stork apparatus or by another suitable means, such as 4 A molecular sieves.
• the reaction may be performed at from about 40 °C to about 200 °C, and preferably at the reflux temperature of the solvent, for from about 1 hour to about 24 hours, preferably about 4 hours to 8 hours.
• the product (8) is preferably purified by chromatography after isolation from the reaction mixture.
• the appropriate aldehyde starting materials (6) may be obtained commercially, or may be prepared easily, for example by reductions of esters or acids with DIBAL or another suitable hydride reducing agent, or oxidation of alcohols under Swem conditions, for example. Aliphatic aldehydes do not work effectively by this route.
• the ketone (5) may, however, include R ⁇ as alkyl groups.
• compound (8) is treated by heating with formamidine acetate in ethoxyethanol or diglyme, followed by purification by flash chromatography.
• compound (8) and ammonium sulfate are heated at reflux in triethyl orthoformate for about 1 to about 8 hours, but preferably about 2 hours.
• the reaction mixture is cooled and added to a mixture of ammonia in ethanol.
• the mixture is stirred for about 12 to 24 hours at 25 °C, then at reflux for from one to 4 hours, and the solvent is removed in vacuo.
• the residue is purified by trituration with chloroform/ethyl acetate, and the product may be converted to a hydrochloride salt by suspension in 3M HCl, followed by lyophilization.
• R*and R 2 are not both hydrogen atoms from the compound of Formula (I) wherein R 1 and R 2 are both hydrogen atoms.
• R 1 or R 2 is loweralkyl this may be accomplished by reaction of the free amino group with the appropriate alkylating reagent, such as an alkyl halide, an alkyl mesylate or an alkyl tosylate, for example, in the presence of a base such as triethylamine or potassium carbonate in a suitable solvent, such as for example, methylene chloride or THF.
• the appropriate alkylating reagent such as an alkyl halide, an alkyl mesylate or an alkyl tosylate, for example, in the presence of a base such as triethylamine or potassium carbonate in a suitable solvent, such as for example, methylene chloride or THF.
• R 1 or R 2 is arylalkyl this may be accomplished by reaction of the free amino group with the appropriate arylalkyl halide, an alkyl mesylate or an alkyl tosylate, for example, in the presence of a base such as triethylamine or potassium carbonate in a suitable solvent, such as for example, methylene chloride or THF.
• a base such as triethylamine or potassium carbonate in a suitable solvent, such as for example, methylene chloride or THF.
• R 1 or R 2 is acyl this may be accomplished by reaction of the free amino group with the appropriate acid anhydride, acyl chloride or activated acyl group, in the presence of a base such as triethylamine or potassium carbonate in a suitable solvent, such as for example, methylene chloride or THF.
• the compound may be prepared by reacting a precursor compound having a halogen atom in place of the amino group at the 4-position with a 5-7 membered ring compound optionally containing an additional oxygen or nitrogen atom.
• the precursor compound having a halogen atom in place of the amino group at the 4-position may be prepared by substitution of treatment with sulfuric acid with heating followed by treatment with triethyl orthoformate for the treatment with formamide (cf.
• Scheme 2 illustrates an alternate method for preparing the compounds (8) of Scheme 1.
• Compounds (5), prepared as described above, are reacted with a dicyanoalkene compound (10) by heating at reflux in an alcohol solvent, for example, ethanol or n-butanol to give the compound (8).
• an alcohol solvent for example, ethanol or n-butanol
• the dicyano compounds (10) may be prepared from the precursor aldehyde (6) by treatment with malononitrile in 1:1 H 2 0:EtOH in the presence of a catalytic amount of glycine according to the method of Bastus (Tetrahedron Lett. , 1963: 955).
• Scheme 3 illustrates an alternate method for preparing compounds of Formula (I) wherein R 4 and R 3 are the same substitutent.
• a bis-substituted acetylene derivative (11) is treated with catecholborane in THF at reflux for from about 8 to about 48 hours, then 4,6- diamino-5-iodo-pyrimidine (12), saturated aqueous sodium bicarbonate, 3N aqueous sodium hydroxide, and tetrakis(triphenylphosphine)palladium(0) are added.
• the mixture is then heated at reflux for from about 8 to about 48 hours to give the substituted pyrimidine compound (13).
• Compound (13) is then treated with the appropriately substituted aldehyde compound (14) to give the desired compound of Formula (I).
• a compound (15) containing the desired R 4 moiety may be reacted with an acyl halide of a halo-substituted compound (16), the ring of which for pu ⁇ oses of illustration only, is shown as a pyridyl ring (eg., 2-halo-5-pyridine carboxylic acid halide), to give the compound (17).
• Compound (17) in turn is heated to decarboxylate and give compound (18).
• compound (16) may be treated in a two-step procedure, first with N- methoxymethylamine HCl, then treating the intermediate with compound (19) under Grignard conditions to prepare compound (18).
• Compound (18) may then be reacted with an appropriate amine compound (20), where compound (20) may be a heterocyclic compound, such as piperidine, py ⁇ olidine, or mo ⁇ holine, for example, or may be a protected or substituted amine, ie. wherein R' and R" are either substituents or amine-protecting groups, or R' and R" are taken together with the N atom to which they are attached to form a heterocyclic ring, in order to prepare compound (5).
• amine compound (20) may be a heterocyclic compound, such as piperidine, py ⁇ olidine, or mo ⁇ holine, for example, or may be a protected or substituted amine, ie. wherein R' and R" are either substituents or amine-protecting groups, or R' and R" are taken together with the N atom to which they are attached to form a heterocyclic ring, in order to prepare compound (5).
• a method of inhibiting adenosine kinase is disclosed.
• an adenosine kinase enzyme is exposed to an effective inhibiting amount of an adenosine kinase inhibitor compound of the present invention.
• Preferred such compounds for use in the method are the same as set forth above.
• Means for determining an effective inhibiting amount are well known in the art.
• the adenosine kinase to be inhibited can be located in vitro, in situ or in vivo.
• adenosine kinase is contacted with the inhibitor compound, typically by adding the compound to an aqueous solution containing the enzyme, radiolabeled substrate adenosine, magnesium chloride and ATP.
• the enzyme can exist in intact cells or in isolated subcellular fractions containing the enzyme.
• the enzyme is then maintained in the presence of the inhibitor for a period of time and under suitable physiological conditions.
• Means for determining maintenance times are well known in the art and depend inter alia on the concentrations of enzyme and the physiological conditions. Suitable physiological conditions are those necessary to maintain adenosine kinase viability and include temperature, acidity, tonicity and the like.
• Inhibition of adenosine kinase can be performed, by example, according to standard procedures well known in the art (Yamada, et al, Comp. Biochem. Physiol. 1982, 71B: 367-372).
• a compound of the invention is typically administered to a fluid perfusing the tissue containing the enzyme.
• That fluid can be a naturally occuring fluid such as blood or plasma or an artificial fluid such as saline, Ringer's solution and the like.
• a method of inhibiting adenosine kinase in vivo is particularly useful in mammals such as humans.
• Administering an inhibitor compound is typically accomplished by the parenteral (e.g., intravenous injection or oral) administration of the compound. The amount administered is an effective inhibiting or therapeutic amount.
• a “therapeutically-effective amount” of the compound of the invention is meant a sufficient amount of the compound to treat or mitigate adenosine kinase related disorders which broadly include those diseases, disorders or conditions which are benefited by inhibition of adenosine kinase, at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention is to be decided by the attending physician within the scope of sound medical judgment.
• the specific therapeutically-effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed; the age, body weight, general health, gender and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with specific compound employed; and the like factors well known in the medical arts and well within the capabilities of attending physicians.
• adenosine kinase activity can be measured using any of the standard procedures well known in the art.
• cells containing adenosine kinase such as IMR-32 human neuroblastoma cells, are cultured in the presence and absence of an inhibitor. Inhibition is measured as the ability to inhibit phosphorylation of endogenous or externally applied * 4 C-adenosine by these cells.
• the cells can be intact or broken.
• adenosine kinase inhibitory activity is determined by studying the effects of inhibitors on adenosine Al and A2 ⁇ receptor binding, adenosine deaminase activity and adenosine transport.
• Compounds of the present invention are effective in inhibiting adenosine kinase activity in vivo. Numerous animal models for studying adenosine kinase activity and the affects of inhibiting such activity are well known in the art.
• adenosine kinase inhibitors have been reported to protect rodents (e.g., mice and rats) from seizures induced by the subcutaneous administration of pentylenetetrazol (PTZ).
• PTZ pentylenetetrazol
• the rodents are injected with various doses of a given inhibitor followed at various times by the subcutaneous administration of from about 10 to about 500 milligrams per kilogram of PTZ. The injected animals are then observed for the onset of seizures.
• the compounds of the invention were tested in vivo in the hot plate test of analgesia in mammals such as mice.
• the compounds of examples 19 and 27 in the procedure described directly below were tested thirty minutes after pretreatment with the drugs (30 ⁇ mol/kg i.p.) for latency to 10th jump (in seconds). The longer the number of seconds, the more effective the drug at masking the pain felt from the hot plate.
• Compound 19 resulted in 142.13 seconds relative to the vehicle alone of 72.76 ⁇ 10.51 seconds.
• Compound 27 resulted in 154.86 seconds.
• Compounds of the invention are therefore potent pain relievers as demonstrated in this animal model.
• mice Male CF1 mice (Charles River) of approximately 25-30 g body weight are pretreated with 10 ml/kg of the test compounds, i.p. or p.o, in groups of 8 animals per dose. At the end of the pretreatment period, the mice are placed in an Omnitech Electronics Automated 16
• Animal Hot Plate Analgesia Monitor (Columbus, OH; Model AHP16AN) in individual, 9.8 x 7.2 x 15.3 cm (1 x w x h) plastic enclosures on top of a copper plate warmed to 55°C. Infared sensors located near die top of each enclosure record beam crossings that occur as the mice jump off of the heated surface. Latency times for each jump are automatically recorded, and latency to both the first and tenth jumps are used for data analysis. Mice that do not reach the criteria of 10 jumps by 180 seconds are immediately removed from the hotplate to avoid tissue damage, and they are assigned the maximum value of 180 seconds as their latency to tenth jump.
• Nociperception Nociperception (Nociception) (Pain)
• Inflammation including conditions such as Septic Shock due to Sepsis Infection
• a method of treating cerebral ischemia, epilepsy, nociperception or nociception, inflammation including conditions such as septic shock due to sepsis infection in a human or lower mammal comprising administering to the mammal a therapeutically effective amount of a compound.
• Alterations in cellular adenosine kinase activity have been observed in certain disorders.
• Adenosine kinase activity was found to be decreased, relative to normal liver, in a variety of rat hepatomas: activity of the enzyme giving a negative correlation with tumor growth rate (Jackson, et al, Br. J. Cancer, 1978, 37: 701-713).
• Adenosine kinase activity was also diminished in regenerating liver after partial hepatectomy in experimental animals (Jackson, et al, Br. J. Cancer, 1978, 37: 701-713). Erythrocyte Adenosine kinase activity was found to be diminished in patients with gout (Nishizawa, et al, Clin. Chim. Acta 1976, 67: 15- 20).
• Lymphocyte adenosine kinase activity was decreased in patients infected with the human immunodeficiency virus (HJ.V) exhibiting symptoms of AIDS, and increased in asymptomatic Hrv-seropositive and HIV-seronegative high-risk subjects, compared to normal healthy controls (Renouf, et al, Clin. Chem. 1989, 35: 1478-1481). It has been suggested that measurement of adenosine kinase activity may prove useful in monitoring the clinical progress of patients with HIV infection (Renouf, et al, Clin. Chem. 1989, 35: 1478-1481).
• Sepsis infection may lead to a systemic inflammatory syndrome (SIRS), characterized by an increase in cytokine production, neutrophil accumulation, hemodynamic effects, and tissue damage or death.
• SIRS systemic inflammatory syndrome
• the ability of adenosine kinase inhibitor to elevate adenosine levels in tissues has been demonstrated to ameliorate syndrome symptoms, due to the known anti-inflammatory effects of adenosine. (Firestein, et al., J. of Immunology, 1994, pp. 5853-5859).
• the ability of adenosine kinase inhibitors to elevate adenosine levels is expected to alleviate pain states, since it has been demonstrated that administration of adenosine or its analogs results in antinociception or antinociperception. (Swaynok, et al, Neuroscience, 1989, 32: No. 3, pp. 557-569).
• Triethylamine (19.6 g, 194 mmol) was added dropwise to a suspension of N,0- dimethylhydroxylamine hydrochloride (6.93 g, 71 mmol) in anhydrous CH2CI2 at 0°C.
• Heptanoylchloride (9.60 g, 65 mmol) was then added dropwise and the reaction was sti ⁇ ed 1 hour.
• the crude product mixture was poured into water and the separated aqueous phase was extracted with CH2CI2. The combined organic layers was washed with aq. HCl, sat.
• Examples 12-24 Following the procedures of Example 11, except substituting the appropriate reagents required for R 5 , R 4 and R 3 as indicated in Table 4 below, compounds of Examples 12-24 were prepared as described in Table 5 below.
• Examples 26-32 Following the procedures of Example 25, except substituting the appropriate reagents required for R 5 , R 4 and R 3 as indicated in Table 6 below, compounds of Examples 26-32 were prepared as described in Table 7 below. Table 6 Examples 26-32
• Examples 33-38 Following the procedures of Example 11, except substituting the appropriate reagents required for R 5 , R 4 and R 3 as indicated in Table 8 below, compounds of Examples 33-38 were prepared as described in Table 9 below.
• Step 39a l-(6-chloro-3-pyridyl)-2-(4-fluorophenyl)ethanone
• Example 11 Step c Following the procedure of Example 11 Step c, except substituting the compound from Step 39b for the compound of Example 11 Step a, and substituting 3- bromobenzaldehyde for the 4-bromo-2-thiophenecarboxaldehyde of Example 1 lb, then carrying the reaction product forward as in Example 1, the title compound was prepared. MS m/z (M+H)+ 557; IR (cm" 1 ) 3433, 3040, 1641, 1602, 1367.
• Example 40-47 Following the procedures of Example 39 and Example 11, except substituting the reagents shown below for the R 3 and R 4 reagents and the reagent shown for the 7-position moiety for the mo ⁇ holine of Example 39 Step b, the compounds shown in Table 10 below were prepared.
• Step 48a l-(6-chloro-3-pyridyl)-3-phenylpropanone
• Step 48b l-(6-morpholinyl-3-pyridyl)-3-phenylpropanone
• Step 48c 4-amino-5-(3-bromophenyl)-6-phenylmethyl-7-(6-morpholinyl-3- pyridinvDpyrido [2,3-dlpyrimidine hydrochloride
• Example 11 Step c Following the procedure of Example 11 Step c, except substituting the compound from Step 48b for the compound of Example 11 Step a, and substituting 3- bromobenzaldehyde for the 4-bromo-2-thiophenecarboxaldehyde of Example 1 lb, then carrying the reaction product forward as in Example 11, the title compound was prepared.

Landscapes

• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Public Health (AREA)
• General Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Neurosurgery (AREA)
• Immunology (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Pain & Pain Management (AREA)
• Diabetes (AREA)
• Heart & Thoracic Surgery (AREA)
• Rheumatology (AREA)
• Cardiology (AREA)
• Endocrinology (AREA)
• Transplantation (AREA)
• Hematology (AREA)
• Urology & Nephrology (AREA)
• Psychiatry (AREA)
• Emergency Medicine (AREA)
• Obesity (AREA)
• Vascular Medicine (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Physical Education & Sports Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=25290123

Family Applications (1)

Country Status (19)

Families Citing this family (4)

Family Cites Families (2)

• 1998
  • 1998-04-13 EP EP98918091A patent/EP0975633A1/en not_active Withdrawn
  • 1998-04-13 IL IL13161798A patent/IL131617A0/xx unknown
  • 1998-04-13 CA CA002286592A patent/CA2286592A1/en not_active Abandoned
  • 1998-04-13 CN CN98804117A patent/CN1252069A/zh active Pending
  • 1998-04-13 SK SK1400-99A patent/SK140099A3/sk unknown
  • 1998-04-13 TR TR1999/02550T patent/TR199902550T2/xx unknown
  • 1998-04-13 PL PL98336265A patent/PL336265A1/xx unknown
  • 1998-04-13 WO PCT/US1998/007201 patent/WO1998046604A1/en not_active Application Discontinuation
  • 1998-04-13 JP JP54408398A patent/JP2001520654A/ja active Pending
  • 1998-04-13 HU HU0001443A patent/HUP0001443A3/hu unknown
  • 1998-04-13 AU AU71080/98A patent/AU741033B2/en not_active Ceased
  • 1998-04-13 NZ NZ337125A patent/NZ337125A/en unknown
  • 1998-04-13 KR KR1019997009552A patent/KR20010006462A/ko not_active Application Discontinuation
  • 1998-04-13 BR BR9809056-9A patent/BR9809056A/pt not_active IP Right Cessation
  • 1998-04-15 ZA ZA983175A patent/ZA983175B/xx unknown
  • 1998-04-15 AR ARP980101734A patent/AR012437A1/es unknown
  • 1998-04-16 CO CO98020978A patent/CO4940470A1/es unknown
• 1999
  • 1999-10-15 NO NO995035A patent/NO995035L/no not_active Application Discontinuation
  • 1999-11-03 BG BG103853A patent/BG103853A/xx unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events